DMACDiaMedica Therapeutics Inc.
What is the market doing?
No clear lean: in an uptrend, but heavily shorted (+10% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +23% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How DMAC is trading
DiaMedica Therapeutics Inc. is +30% over the past year while the S&P 500 is +16%: 14 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +23%
vs 200-day average · a clear uptrend
- RSI (14)
- 54
RSI (14) · neutral
- Below its 52-week high
- 7.2%
Below its 52-week high
Details›
- Last close2026-10-23
- $8.71
- 1 monthS&P 500 −0.94%
- +11%
- 1 yearS&P 500 +16%
- +30%
- 5 yearsS&P 500 +86%
- +112%
- vs 50-day average$7.36
- +18%
- 52-week high
- $9.39
- 52-week low
- $5.33
- Annualised volatility
- 68%
| Year | Return |
|---|---|
| 2026 (year to date) | +9.4% |
| 2025 | +47% |
| 2024 | +91% |
| 2023 | +80% |
| 2022 | −58% |
| 2021 | −63% |
| 2020 | +109% |
| 2019 | +67% |
| 2018 | −42% |
| 2017 | +128% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | −2.5% |
| Feb | 10 | 8 of 10 | +8.5% |
| Mar | 10 | 3 of 10 | −1.6% |
| Apr | 10 | 6 of 10 | +5.3% |
| May | 10 | 5 of 10 | +4.9% |
| Jun | 10 | 6 of 10 | +16% |
| Jul | 11 | 3 of 11 | −11% |
| Aug | 11 | 6 of 11 | +1.9% |
| Sep | 11 | 5 of 11 | +1.7% |
| Oct | 11 | 5 of 11 | +0.95% |
| Nov | 10 | 6 of 10 | +2.4% |
| Dec | 10 | 4 of 10 | +11% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Biotechnology
Ranks #121 of 194 by RyuScore